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BACKGROUND: MSMB, a gene coding for b-microseminoprotein, has been identified as a candidate susceptibility gene for prostate
cancer (PrCa) in two genome-wide association studies (GWAS). SNP rs10993994 is 2bp upstream of the transcription initiation site
of MSMB and was identified as an associated PrCa risk variant. The MSMB protein is underexpressed in PrCa and it was previously
proposed to be an independent marker for the recurrence of cancer after radical prostatectomy.
METHODS: In this study, the coding region of this gene and 1500bp upstream of the 50UTR has been sequenced in germline DNA in
192 PrCa patients with family history. To evaluate the possible effects of these variants we used in silico analysis.
RESULTS: No deleterious mutations were identified, however, nine new sequence variants were found, most of these in the promoter
and 50UTR region. In silico analysis suggests that four of these SNPs are likely to have some effect on gene expression either by
affecting ubiquitous or prostate-specific transcription factor (TF)-binding sites or modifying splicing efficiency.
INTERPRETATION: We conclude that MSMB is unlikely to be a familial PrCa gene and propose that the high-risk alleles of the SNPs in
the 50UTR effect PrCa risk by modifying MSMB gene expression in response to hormones in a tissue-specific manner.
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Prostate cancer (PrCa) is the most common cancer in men in the
western world, with 34000 new cases every year and a lifetime risk
of 1 in 14 in the United Kingdom (Cancer Research UK Factsheets,
2008). However, its aetiology remains poorly understood. The
substantial worldwide variation in incidence rates suggests that
there are lifestyle risk factors, but none have been identified
definitively. Apart from demographic factors, the only well-
established risk factor for PrCa is family history. The risk of the
disease in first-degree relatives of cases is approximately twice that
of the general population (Carter et al, 1992; Goldgar et al, 1994;
Eeles, 1999; Hemminki and Czene, 2002; Gronberg, 2003; Edwards
and Eeles, 2004). Familial risk is four-fold greater amongst close
relatives of cases under 60-years old. Men with two or more
affected relatives are at even higher risk. Analyses of the Nordic
twin registries show higher risks in monozygotic compared with
dizygotic twins, thereby supporting the hypothesis that much
familial aggregation is due to genetic factors rather than shared
lifestyle factors (Lichtenstein et al, 2000). Epidemiological studies
consistently demonstrate aggregation of PrCa in families, consistent
with a multi-genetic origin.
To identify some of the multiple susceptibility loci we recently
carried out a genome-wide association study (GWAS) of B550000
single base pair genetic variants (SNPs) in 1854 PrCa cases and 1894
controls. Seven new susceptibility loci were validated in a further set
of 3650 PrCa cases and 3940 controls containing several plausible
candidate genes, one of which was on chromosome 10 (Eeles et al,
2008). Single base pair genetic variants rs10993994 and rs7920517
lie within an LD block of B100kb on chromosome 10, containing
the b-microseminoprotein beta gene, MSMB. The most strongly
associated SNP, rs10993994, lies 2bp upstream of the transcription
start site of MSMB. This association was also reported by the CGEM
study (Thomas et al, 2008). MSMB codes for PSP94, a prostatic
secretory protein, synthesised almost exclusively in the prostate
gland and it is the major constituent of seminal plasma. PSP94
functions in growth regulation and induction of apoptosis in PrCa
cells (Garde et al, 1999) and, as it leaks into the blood, its serum level
can be measured. There is a correlation between a reduced level of
PSP94 and PrCa progression (Reeves et al, 2006; Bjartell, 2007), after
radical prostatectomy. Thus, it is clear that the regulation of the
expression of MSMB is a key element in PrCa development and any
sequence variant, which has an effect on the level of MSMB gene
expression would be a good candidate for a causal variant.
The location of the rs10993994 and the strength of the
association (P¼10
 17) raise the possibility that this SNP may be
causally related to disease risk, although this remains to be proven.
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sHowever, GWAS are designed to tag common variants, and
associations mediated by rare variants may have been missed.
In order to establish the contribution of variants at this locus
to familial PrCa and to explore the possibility that there may
be additional disease-associated variants in the MSMB gene,
we re-sequenced the genomic sequence of the MSMB gene
including a B1500bp region upstream of the transcription start
site in 192 PrCa cases with strong family history of the disease.
MATERIALS AND METHODS
Whole blood samples from PrCa cases were collected as part of
the UK Genetic Prostate Cancer Study (UKGPCS) at the Institute
of Cancer Research (http://www.icr.ac.uk). We have selected 192
families with three or more cases of PrCa. A sample from one
person per family was used for sequence analysis and wherever
possible this was the youngest family member affected with PrCa.
Control samples were from the ProtecT study; this is a national
study of community-based PSA testing and a randomised trial of
subsequent PrCa treatment (Donovan et al, 2003). Men between
the ages of 50 and 69 years are being recruited through general
practices in nine regions in the UK. DNA was extracted from their
peripheral blood using standard methods as described previously
(Eeles et al, 2008).
For the familial cases the full coding sequence of the MSMB
gene, exon–intron boundaries and a B1500bp region of the
50UTR region was analysed by sequencing using the BigDye
Terminator Cycle Sequencing kit (v3.1) and a 3730xl DNA
Analyzer, (ABI Perkin Elmer, Foster City, CA, USA). Control
samples were sequenced only for the 50UTR region to assess the
allele distribution of the newly discovered promoter SNPs. One
new variant, rs12770171 was analysed by the 50nuclease assay
(Taqman) using the ABIPrism 7900HT sequence detection system
according to the manufacturer’s instructions. Primers and probes
were supplied directly by Applied Biosystems, Foster City, CA,
USA (http://www.appliedbiosystems.com/) as Assays-By-Design.
To identify the potential effects of sequence variants in the
promoter and intronic regions, 161 nucleotide sequences around
each SNP were taken from Ensembl (FASTA) and the alternative
alleles inserted. These sequences were submitted to Genomatix-
Suite MatInspector, which offers the most complete library
available for transcription factor (TF)-binding sites (Cartharius
et al, 2005) and we also applied a tissue filter specific for prostate.
Associations between SNP genotypes and PrCa risk were tested
using a Cochrane–Armitage trend test and genotype-specific risks
were estimated as odds ratios (ORs) with associated 95%
confidence interval (95% CI). For Hardy–Weinberg equilibrium
and Armitage trend testing, we used the public software developed
by Tim M Strom and Thomas F Wienker (http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl). For the haplotype analysis we used Haploview
(Barrett et al, 2005) and Haplo.Stats (Schaid et al, 2002).
RESULTS
We have sequenced the MSMB gene and a 1500bp 50UTR region in
192 blood DNA samples with strong family history (X3PrCa cases
in the family). No deleterious mutation was found in any of the
exons, but we identified nine new SNP sequence variants as well as
six other previously known SNPs in HapMap. The list of all the
SNPs in this region is shown in Table 1.
Four of the new variants are in the 50 UTR of the MSMB gene,
these were found in addition to six previously known SNPs in this
region. This region has been characterised previously as the
proximal promoter region for MSMB. In all, 10 out of 17 SNPs
identified lie in the promoter region. Of this region, 1500bp was
resequenced in 192 control samples to analyse the relative frequency
of the three commonly known SNPs in the 192 PrCa cases and 192
control samples (Table 2a). SNP2 (ENSSNP10237085), SNP8
(rs12770171) and SNP9, (rs1093994) all were significantly associated
with PrCa risk. Single base pair genetic variants was a previously
uncharacterised SNP (it was not genotyped in HapMap Phase 2). To
further investigate its association with PrCa risk, we genotyped
blood DNA from 3268 cases and 3366 controls. We found strong
evidence for an association between rs12770171 and PrCa risk
(P¼1.41 10
 12), however, this SNP is in LD with rs10993994
(r
2¼0.32) and multiple logistic regression and haplotype analysis
revealed that there was no evidence for an independent association
with rs12770171 after adjustment for rs10993994 (Table 3).
Table 1 List of SNPs identified by re-sequencing of 192 familial prostate cancer cases
SNP NCBI 36 coordinates dbSNP ID
Designation (VEGA transcipt
OTTHUMG00000018212) Genotype No (of 192)
SNP 1 10: 51218441 New  1063 T4CC T 1
SNP 2 10: 51218461 rs61847070  1043 T4CT C 3 4
CC 1
SNP3 10: 51218615 New  889 G4CG C 4
SNP4 10: 51219036 New  468 T4CT C 1
SNP5 10: 51219205 rs12247790  299 T4GG G 1
SNP6 51219227^51219228 rs10669586  276 indelCT 6
SNP7 10: 51219266 New  238 C4TT C 1
SNP8 10: 51219320 rs12770171  184 C4TC T 7 2
TT 8
SNP9 10: 51219502 rs10993994  2T 4CT C 9 1
TT 69
SNP10 10: 51219539 rs41274660 UTR  19 T4GT G 7
GG 1
SNP11 10: 51225699 New IVS1  38 T4GT G 1
SNP12 10: 51225716 New IVS1  21 T4CT C 1
SNP13 10: 51226117 rs2075894 IVS2 +275 T4CT C 5 1
CC 2
SNP14 10: 51226665 New IVS2  92 G4TG T 2
SNP15 10: 51226682 New IVS2  75 G4TG T 1
SNP16 10: 51226927 rs10994385 IVS3 +65 G4CG C 5 2
CC 1
SNP17 10: 51232109 New IVS3  168 C4TC T 1
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sFunctional relevance of the sequence variants was assessed
in silico, by examining the regions around the 17 SNPs for
conservation and allele-specific splice factor or TF binding.
SNP8 lies in a biochemically characterised enhancer region of
the promoter ( 275 to  206 upstream of the start ATG, Ochiai
et al, 1995) but no TF is predicted to bind across SNP8. SNPs 7, 8, 9
(the original best hit) and 10 are all in a 400bp region, ending in the
ATG transcription start site. Of the four SNPs, 8 and 9 lie in the best-
conserved sequence, with SNP8 being the best conserved SNP across
mammals (Supplementary Table 1). SNP9 (rs10993994) is predicted to
change the binding site for the ubiquitous CCAAT and Gli–Kreupel
TFs. SNPs 7 and 10 are predicted to have allele-specific TF binding in
prostate tissue. SNP7 is predicted to bind glucocorticoid receptor TFs,
including androgen and progesterone receptors, NR3C1&2 (nuclear
receptor subfamily 3, group C) and aldosterone-receptor TFs. The
rare allele of SNP7 (c.-238 C4T) increases predicted glucocorticoid
binding two-fold, and is predicted to displace binding of ubiquitous
E-box TFs (including Myc). The common allele of SNP10 (c.-19
T4G), is predicted to bind NKX homeobox domain TFs. The in-silico
data for SNPs7–10 are summarised in Figure 1.
Glucocorticoid TF-binding sites are also found across SNP15
and close to (within 50bp of) SNP11/12, SNP14 and SNP16. Allele-
specific alterations in binding of splice factors SFp40, ASP/SF2 are
predicted for SNP12.
The two SNPs predicted to have prostate-tissue and allele-
specific effects on TF binding are rare sequence variants; SNP7 has
not been previously reported and we found it in only 1 out of 192
case samples (this variant was also present in a sibling with PrCa);
SNP10, rs41274660, is found at a frequency of 7 out of 192
heterozygotes and 1 out of 192 homozygotes in our familial cases
compared with 6 heterozygotes in 192 controls; therefore there is
no evidence that this SNP is associated with PrCa risk.
DISCUSSION
We present the resequencing results of the MSMB gene and its
50UTR region in familial PrCa cases and controls. Recently, two
GWAS identified MSMB as a PrCa susceptibility locus. Both
studies found that SNP rs10993994 is associated with PrCa risk,
with a per allele OR of 1.25, P¼10
 13 to  29.
Resequencing germline DNA from 192 familial PrCa cases did
not find any deleterious mutations in the coding region of MSMB,
hence it is unlikely that this gene is altered by rare deleterious
coding mutations in familial PrCa. We have identified nine new
sequence variants and using bioinformatics tools, have assessed
their predicted effect on MSMB gene expression/regulation. The
MSMB gene consists of four exons and is located on chromosome
10q11.2. In the upstream region of MSMB there are many putative
transcription regulatory elements and it has been shown that the
proximal promoter regions,  275–207 and  186–128, function
in a prostate-specific manner. We have identified several new
sequence variants in the non-coding intronic and promoter
regions. SNP8, rs12770171, a previously uncharacterised SNP
was found to be strongly associated with PrCa in our familial
set, however, this association could be explained by the correla-
tion between this SNP and rs10994993 and therefore it is not
independently associated. In silico analysis revealed that SNP8
(rs12770171) lies within a known enhancer region and we propose
that it might have an effect on gene regulation. The most strongly
associated SNP, SNP9 (rs10993994) is predicted to change the
binding site for the ubiquitous CCAAT and Gli–Kreupel TFs.
In vitro studies by Buckland et al (2005) showed that both SNPs 8
and 9 have a substantial effect on the function of MSMB, reducing
its activity by 60–70%. Some of the other SNPs are, however, also
predicted to affect the expression level of MSMB, in particular,
the very rare, high-risk allele of SNP7 amplifies the binding site
for androgen and progesterone receptor in prostate tissue at the
expense of a ubiquitous cell cycle/growth TF. As a result, a subtle
alteration in the control of MSMB expression, changing ubiquitous
cell-cycle/growth regulation to hormone regulation is predicted in
the presence of the high-risk allele. As we found this alteration in
only 1 out of 192 PrCa families, this variant could be a rare mutation
predisposing to PrCa. SNP10 is predicted to bind NKX homeobox
domain TFs and this would lead to allele-specific tissue specificity
as well as hormonal regulation. Altogether as SNPs 7–10 are all
predicted to influence the regulation of gene expression, their
additive effects could result in a large variation in MSMB expression.
Yeager et al (2009), have reported the resequence analysis of
a 97kb region containing the MSMB gene using DNA from
Table 2 (a) Common SNPs with significant difference in the frequency of alleles in 192 familial cases and 192 controls and (b) Haplotype analysis of the









SNP2 10: 51218461 ENSSNP10237085 C 0.094 0.048 0.0172
SNP8 10: 51219320 rs12770171 T 0.236 0.151 0.0036








SNP 2,8 and 9
TCC 0.597 210.5:173.5, 234.6:127.4 0.548, 0.648 7.721 0.0055
TCT 0.209 83.2:300.8, 72.9:289.1 0.217, 0.201 0.259 0.6111
TTT 0.122 54.4:329.6, 36.4:325.6 0.142, 0.101 2.934 0.0868
CTT 0.073 36.0:348.0, 18.1:343.9 0.094, 0.050 5.287 0.0215
Table 3 Haplotype analysis of SNP 8 rs1277017 and SNP 9
rs10,993,994 using our data from stage1 and 2 genome-wide association
study (GWAS) adjusted for strata (Eeles et al, 2008)
Haplotype
N
a rs10993994 rs1277017 P-value Freq
b Odds ratio
c (OR)
1 1 C 1 C 0.580 1
2 1 C 2 T 0.35 0.0021 1.38 (0.71–2.04)
3 2 T 1 C 7.0 10
 18 0.210 1.35 (1.28–1.42)
4 2 T 2 T 3.7 10
 19 0.208 1.37 (1.30–1.44)
aHaplotype number.
bHaplotype frequencies.
cOdds ratio and 95% confidence interval.
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s70 individuals (36 PrCa cases and 28 controls). They identified
348 SNPs, of which 157 were new. Similarly for us, they did not
discover any SNPs in perfect LD with rs10993994 or any coding
SNPs in MSMB. As they only list the common SNPs (MAF45%),
which are catalogued in dbSNP we are unable to make a
comparison with the less common SNPs or rare variants reported
here. Considering the difference between the sample sets, it is
likely that the rare variants found by us were not identified in the
study of Yeager et al (2009).
In a recent functional study it was shown that the risk allele of
SNP9, rs10993994, had only 13% of the promoter activity of the wild-
type allele in the PrCa model LNCaP cell line and there was a dose–
dependant increase in MSMB promoter activity in the wild-type
allele with the synthetic androgen R1881 (Chang et al, 2009). In
addition, Lou et al (2009) have also shown a significant effect of the
risk allele on gene expression in vitro and that the non-risk allele
preferentially binds to the CREB TF. This provides further evidence
that rs10993994 (SNP9) is likely to be the strongest causative variant.
However, the functional effects of all the above described variants on
gene expression will need to be tested in vivo on samples whose DNA
has been genotyped for all these SNPs. It is possible that allele-
specific alterations in splicing are combined with effects on
transcriptional levels. A SNP lying within a known, biologically
active element is most likely to have an effect, so the in silico
predictions for SNP9 agree with the laboratory observations.
Although a SNP within a biologically validated TF-binding site is
a good indicator for the possible functional effect on transcription,
it is known that a large proportion of functional SNPs do not lie
within the known consensus of TF-binding sites. Functional SNPs
may exert their effect by other mechanisms, such as changing the
structure of the DNA or by affecting splicing. Ultimately one would
need direct evidence of functionality from in vitro/in vivo models,
but the collection of expression and segregation analysis data
would also be helpful in this assessment.
The protein product of MSMB is PSP94, a small cysteine-rich
protein. It is abundantly expressed in seminal fluid, possibly
coating the sperm, and is also found in blood and mucus. Protein
expression is reduced in PrCa, so its gradual loss is associated
with the development of PrCa. Its expression is regulated by the
polycomb group protein EZH2, and the expression of MSMB can
be silenced by trimethylation. PSP94 has roles in growth regulation
and the induction of apoptosis in PrCa cells and as it leaks into
the blood, its serum level can be measured. As there is a tight
correlation between the level of PSP94 and PrCa progression
(Reeves et al, 2006; Bjartell, 2007), PSP94 is believed to be an
independent predictor of recurrence of cancer after radical
prostatectomy. Based on these observations it is clear that the
regulation of the expression of MSMB is a key element in PrCa
development and any sequence variant that has an effect on the
level of gene expression is a good candidate for a causal variant.
In summary, we have not found any deleterious mutations in the
coding sequences of MSMB in familial PrCa. This study has a 90%
power to detect a rare mutation with a frequency of 41%. Based
on this and other recent studies it is likely that SNP9, rs10993994,
is the causative variant in the association of MSMB with PrCa risk.
However, through resequencing, we have identified several new
SNPs in the promoter region, which are also predicted to have
some effect on splicing/transcription of the MSMB gene. A very
rare new variant, whose effect cannot be statistically validated
and rs41274660, a previously described variant are predicted to
have a direct effect on prostate-specific TF-binding sites, one
of which include androgen/progesterone/aldosterone receptors.
Further functional studies are needed to fully establish the signif-
icance of these sequence variants individually or in combination
in PrCa predisposition.
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Figure 1 Physical disposition along chromosome 10 of new SNPs from prostate cancer (PrCa) patients, showing previously characterised glucocorticoid-
responsive elements and enhancers, transcripts and repetitive elements. In silico analysis showed that SNP7 is predicted to alter the response to
glucocorticoid transcription factors (TFs) in prostate tissue; SNP8 is the most conserved and falls within an enhancer; SNP9 (rs10993994) is predicted to
change the binding site for the ubiquitous CCAAT and Gli–Kreupel TFs, whereas only the common allele of SNP10 is predicted to bind homeobox TFs.
SNPs 13 and 14 are also highly conserved; binding of splice factors is predicted to be altered by SNP14 alleles.
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